Genmab/Semaia: Firms To Share Costs, Revenues
COPENHAGEN -(Dow Jones)- Danish biotechnology company Genmab A/S (K.GEM) said Wednesday it has established an alliance with Netherlands -based Semaia Pharmaceuticals to develop new antibody therapeutic products.
The companies gave no specific financial details about the arrangement.
Genmab said it and Semaia will collaborate on the research, development and any eventual commercialization of the new antibody products, and will share equally the development costs and revenues generated from out-licensing or sales of the products.
Under the terms of the partnership, Genmab will utilize its fully human antibody technology and preclinical expertise to create and develop new products for up to four novel cancer disease target molecules discovered and validated by Semaia Pharmaceuticals.
Genmab said the partnership unites its broad antibody development capabilities and array of preclinical tools to generate and characterize fully human antibodies with Semaia Pharmaceuticals' skills in finding and validating novel cancer targets.
"Semaia Pharmaceuticals represents Genmab's sixth partnership signed this year, a mark that Genmab is building a solid foundation for the continuing development of its broad pipeline of products," said Lisa N. Drakeman Ph.D., Genmab's chief executive officer.
"Genmab is Semaia's first cooperation partner," said Rian de Jonge Ph.D., chief executive officer. "As a young and innovative biotech company, we are extremely proud of the fact that we will be cooperating with Genmab in the future. By working on antibodies, we create added value which means we increase the success rate in the development of marketable drugs." |
